survey. Patients that underwent an anterior/middle scalene block and subsequent first rib resection were identified. Patient demographics, personal disability from symptoms, and outcomes after surgery were recorded and compared using c 2 analysis for categorical variables and the t test for continuous variables.
PC126. Embolization Techniques for High-Flow Arteriovenous Malformations in Parkes-Weber Syndrome
Suroosh Marzban, Allan M. Conway, Heather Short, Gary Giangola, Alfio Carroccio, Robert Rosen. Lenox Hill Heart & Vascular Institute of New York, New York, NY Objectives: Multiple high-flow arteriovenous malformations (AVMs) are the hallmark of Parkes-Weber syndrome (PWS), unlike other low-flow congenital malformations, such as those seen in Klippel-Trenaunay syndrome. These are difficult to treat and surgical resection has historically shown poor outcomes. The aim of this study was to assess the management of PWS in the current era.
Methods: A retrospective review was performed from 2004 to 2017 on all patients presenting to a single institution for the management of PWS. Presentation, techniques, complications, and outcomes were reviewed.
Results: Fourteen patients (50% male) with PWS were seen at our institution and mean age was 19.9 years (range, 4.7-68.8 years). The lower extremity was affected in 12 (86%) and the upper extremity in 2 (14%) patients. All patients presented with pain and swelling in the affected limb. Seven patients (50%) presented with ulcers, of whom three (43%) had extensive wounds. Five patients (36%) had echocardiographic evidence of high-output cardiac failure. All patients underwent angiography with the intention to treat. Three patients (21%) were found to have diffuse arteriovenous communication with no discrete AVM nidus and thus did not undergo intervention. The remaining 11 patients (79%) underwent transcatheter embolization of the AVM's arterial inflow. Six patients (55%) required multiple or staged inflow embolization procedures, with a mean of 3.3 interventions (range, 1-10 interventions). Thirty-six arterial embolization procedures were performed in total. n-Butyl cyanoacrylate adhesive was used in 22 (72%), microspheres in 8 (22%), and a combination of coils and adhesive in 2 (6%) cases. Technical angiographic success was seen in all patients. Six patients (55%) also had interventions to treat the venous component of the malformation, either concomitantly or during a separate procedure. This included radiofrequency ablation in one (17%), coil embolization in one (17%), sodium tetradecyl sulfate (STS) sclerotherapy in two (33%), and a combination of STS, coil embolization, and vein stripping in two (33%) patients. Ten patients (91%) experienced a partial response and one patient (9%) experienced no response to treatment. No patients had a complete response, as expected with the diffuse nature of this disease. There were no periprocedural complications. Two of three patients with complex wounds required major amputations for gangrene, including one above-the-knee and one below-theknee amputation at 128 months and 66 months after the index procedure, respectively.
Conclusions: High-flow AVMs in PWS can be successfully treated by a transcatheter approach. Multiple interventions are usually required. Patients with extensive wounds remain at risk for loss of limb.
Author Disclosures: A. Carroccio: Nothing to disclose; A. M. Conway: Nothing to disclose; G. Giangola: Nothing to disclose; S. Marzban: Nothing to disclose; R. Rosen: Nothing to disclose; H. Short: Nothing to disclose.
PC128.

Serum Resistin Is Associated With Impaired Endothelial Function and Poor Outcomes in Patients With Peripheral Artery Disease
Joel L. Ramirez, Sukaynah A. Khetani, Greg J. Zahner, Melinda S. Schaller, Warren J. Gasper, Nancy K. Hills, Anne L. Schafer, S. Marlene Grenon. University of California San Francisco, San Francisco, Calif
Objectives: Resistin is a hormone secreted by adipocytes that has been associated with metabolic syndrome and cardiovascular disease. However, less is known on the role of resistin in patients with peripheral artery disease (PAD). The present study seeks to understand the relationship of serum resistin with endothelial function and cardiovascular outcomes in patients with PAD. We hypothesize that increased serum resistin is associated with worse endothelial function and an increased rate of major adverse cardiac events (MACE).
Methods: One-hundred six patients who presented to clinic with complaints of claudication and an ankle-brachial index of <0.9 or history of revascularization for symptomatic PAD were recruited between 2011 and 2016. Patients were excluded if they had acute illness, renal or hepatic disease, or were taking immunosuppressants. Resistin was assayed using commercially available ELISA kits. Endothelial function was measured via brachial artery flow-mediated vasodilation (FMD) at baseline. Incident MACE were identified by subsequent chart review and defined as a composite end point of myocardial infarction, coronary revascularization, stroke, or death from a cardiac cause. Cox proportional hazards models were used to calculate hazard ratios for MACE.
Results: At baseline, despite similar Rutherford scores, medical comorbidities, and medication use, FMD was significantly lower with increasing resistin quartile (I, 9.1 6 3.3%; II, 7.1 6 3.5%; III, 5.8 6 4.0%; IV, 5.6 6 3.5%; P ¼ .002; Fig 1) (interquartile range, 29-45) , 21 patients experienced the primary end point. In a Cox proportional hazards model adjusted for smoking status, coronary artery disease, and age, resistin was independently associated with an increased rate of MACE (HR, 1.10; 95% CI, 1.00-1.20; P ¼ .04; Fig 2) .
